Currently, point-of-care CRP testing is approved for screening of active TB in people living with HIV, but there is little role of this biomarker in monitoring treatment response due to inconclusive evidence regarding its association with bacteriological endpoints [14,17,18,19,21,22,23]. The gene discussed is CRP; the disease is tuberculosis.